Abstract:We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma patients. A total of 414 patients received three 21-day cycles of VCD prior to autologous stem-cell transplantation (ASCT). Most common grade ≥3 adverse events were leucopenia (31·4%) and thrombocytopenia (6·8%). The overall response rate (ORR) by investigator-based assessment was 85·4%. Most patients (74%) underwent successful central laboratory-based molecular… Show more
“…Aft er a median follow-up of 68.7 months, they reported good 8-year PFS (43%) and OS (67%) following allogeneic transplant in 61 patients who received escalating DLI. Low GVHD incidence was also observed (33%) with no DLI related mortality [34] in the same reference. On the other hand, Edwin et al did not observe a diff erence in the incidence of GVHD when the patients received DLI at less than one year versus > 1 year aft er BMT, as shown by Alyea et al [40,42].…”
Section: Graft-versus-myeloma Effect and Donor Lymphocyte Infusions (supporting
Multiple myeloma is still an incurable cancer notwithstanding the myriads of chemo-and immunotherapies, Th ere are more than 20,000 cases of MM diagnosed per year in the US. Bone marrow transplant is still considered the cornerstone for MM therapy, at least for now. Th e evident need is to revisit the conventional treatment approaches to cellular therapy, such as auto-and/or allogeneic hematopoietic stem cell transplantation (HCT), and develop the new options, like CAR-T cells. Th is review article will present and discuss diff erent approaches to modern treatment of MM, by summarizing the results of clinical studies, raising feasibility and effi ciency questions, and answering some of them which have been already resolved in numerous trials performed with CAR-T cells.
“…Aft er a median follow-up of 68.7 months, they reported good 8-year PFS (43%) and OS (67%) following allogeneic transplant in 61 patients who received escalating DLI. Low GVHD incidence was also observed (33%) with no DLI related mortality [34] in the same reference. On the other hand, Edwin et al did not observe a diff erence in the incidence of GVHD when the patients received DLI at less than one year versus > 1 year aft er BMT, as shown by Alyea et al [40,42].…”
Section: Graft-versus-myeloma Effect and Donor Lymphocyte Infusions (supporting
Multiple myeloma is still an incurable cancer notwithstanding the myriads of chemo-and immunotherapies, Th ere are more than 20,000 cases of MM diagnosed per year in the US. Bone marrow transplant is still considered the cornerstone for MM therapy, at least for now. Th e evident need is to revisit the conventional treatment approaches to cellular therapy, such as auto-and/or allogeneic hematopoietic stem cell transplantation (HCT), and develop the new options, like CAR-T cells. Th is review article will present and discuss diff erent approaches to modern treatment of MM, by summarizing the results of clinical studies, raising feasibility and effi ciency questions, and answering some of them which have been already resolved in numerous trials performed with CAR-T cells.
“…VCD has demonstrated a high response rate in prospective phase II and phase III clinical trials [24,[39][40][41]. The IFM conducted a randomized trial of head-to-head comparison between VTD and VCD prior to ASCT in patients with untreated MM [27].…”
Section: Bortezomib Thalidomide and Dexamethasone (Vtd)mentioning
Use of proteasome inhibitors (PIs) has been the therapeutic backbone of myeloma treatment over the past decade. Many PIs are being developed and evaluated in the preclinical and clinical setting. The first-in-class PI, bortezomib, was approved by the US food and drug administration in 2003. Carfilzomib is a next-generation PI, which selectively and irreversibly inhibits proteasome enzymatic activities in a dose-dependent manner. Ixazomib was the first oral PI to be developed and has a robust efficacy and favorable safety profile in patients with multiple myeloma. These PIs, together with other agents, including alkylators, immunomodulatory drugs, and monoclonal antibodies, have been incorporated into several regimens. This review summarizes the biological effects and the results of clinical trials investigating PI-based combination regimens and novel investigational inhibitors and discusses the future perspective in the treatment of multiple myeloma.
“…These include bortezomibcyclophosphamide-dexamethasone (VCD), bortezomiblenalidomide-dexamethasone (VRD or VTD), bortezomibmelphalan-prednisone (VMP) or antibody-combinations, autologous stem cell transplantation (ASCT) and 2-drug combinations, such as lenalidomide-dexamethasone (Rd), bortezomib-dexamethasone (Vd), and others. 3,[20][21][22] These largely expanded therapeutic strategies, including immunotherapies, 23 have significantly evolved in recent years, but the beneficial effect is not seen across the age spectrum, with intermediate-fit or frail patients not obtaining the maximal benefit from such new treatment. Part of this failure to achieve benefit relates to the host biology of older patients.…”
Section: Instruments To Assess Vulnerability Due To Increased Treatmementioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.